TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11429352
Drug: Inhaled anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled anesthesia with isoflurane
Study: 9605995
Drug: Bereavement support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bereavement support group intervention (10-week, once weekly, 90-min/session)
Study: 7993207
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment with a 1 microgram/h ganciclovir implant
Study: 7993207
Drug: Ganciclovir implant
Normalized name: ganciclovir Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir implant
Study: 2691815
Drug: 15 g.100
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g.100 ml‐1 glucose (G)
Study: 2691815
Drug: 15 g.100
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g.100 ml‐1 maltodextrin plus 3 g.100 ml‐1 fructose (MD)
Study: 2691815
Drug: 7 g.100
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 g.100 ml‐1 sucrose (I)
Study: 26278231
Drug: Venlafaxine extended-release
Normalized name: Desvenlafaxine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine extended-release (#300 mg per day) for 12-14 weeks
Study: 21654268
Drug: Febuxostat 60
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat 60 mg/d
Study: 19781407
Drug: Intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive statin therapy (atorvastatin, 20 or 40 mg/d, or equivalent dose of other statins)
Study: 19781407
Drug: Standard statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard statin therapy (atorvastatin, 10 mg/d, or equivalent dose of other statins)
Study: 15502598
Drug: Paroxetine (10‐50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (10‐50 mg/day)
Study: 11775645
Drug: Essaven gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essaven gel (EG) - single acute application
Study: 7919329
Drug: rhIL‐3 (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL‐3 (2.5 or 5.0 micrograms/kg/day) administered by subcutaneous injection for either 5 or 10 days starting 4 hours after the marrow infusion followed by rhGM‐CSF (250 micrograms/m2/d as a 2‐hour intravenous infusion) until ANC > or = 1,500/microL for 3 consecutive days or until day 27 posttransplant.
Study: 7919329
Drug: rhGM‐CSF (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGM‐CSF (250 micrograms/m2/d as a 2‐hour intravenous infusion) administered after rhIL‐3.
Study: 30054842
Drug: CEGP-003 spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEGP-003 spray
Study: 20715595
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day of algal DHA
Study: 16546105
Drug: MMC, 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMC, 0.2 mg/ml applied for three minutes (Group 1)
Study: 16546105
Drug: Conjunctival autografting
Normalized name: Sus scrofa conjunctiva preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjunctival autografting combined with one minute application of MMC, 0.2 mg/ml (Group 4)
Study: 10660096
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 800 mg/day for 12 weeks
Study: 380253
Drug: Paracetamol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (0.5 g x 4 for 3 days)
Study: 380253
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (0.5 g x 4 for 3 days)
Study: 367795
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (Paracetamol, Acetylsalicylic acid, Placebo)
Study: 30404139
Drug: Random Forest
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random Forest model using a combination of three NDVI characteristics, three phenological characteristics, and two curve parameters as predictors for sunflower yield estimation
Study: 22238353
Drug: Octreotide-LAR treatment
Normalized name: octreotide
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide-LAR treatment for 48 months
Study: 22238353
Drug: Inactive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive group after treatment
Study: 22238353
Drug: Correlation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation with homeostasis model of assessment‐insulin resistance
Study: 22238353
Drug: Correlation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation with growth hormone (GH)
Study: 18094424
Drug: L-arginine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (30 g daily for 3 days)
Study: 15951310
Drug: 4% dimeticone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% dimeticone lotion (applied for eight hours or overnight)
Study: 10449124
Drug: Aldose reductase
Normalized name: Aldose reductase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldose reductase inhibitor (ARI) zenarestat
Study: 8714853
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream applied 60 min prior to local anesthesia
Study: 8714853
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no EMLA cream)
Study: 2220573
Drug: No ECG
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ECG (n = 6 concurrent control patients)
Study: 393076
Drug: Alcohol 1.2
Normalized name: dichlorobenzyl alcohol 1.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol 1.2 g/kg
Study: 393076
Drug: Diazepam 2
Normalized name: diazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 2 mg
Study: 29727535
Drug: Pancreatic kininogenase
Normalized name: kininogenase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic kininogenase (120 u, tid) and sildenafil (25 mg, qd at bedtime)
Study: 29727535
Drug: Sildenafil (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (25 mg, qd at bedtime)
Study: 21087222
Drug: Individualized nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized nutritional treatment from a dietitian in the hospital and three home visits after discharge
Study: 21087222
Drug: Individualized nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized nutritional treatment
Study: 9697784
Drug: General endotracheal
Approvals — FDA: no, EMA: no, PMDA: no
Description: General endotracheal anesthesia with postoperative intravenous morphine patient-controlled analgesia